• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迟发性运动障碍评定量表。

A rating scale for tardive dyskinesia.

作者信息

Simpson G M, Lee J H, Zoubok B, Gardos G

出版信息

Psychopharmacology (Berl). 1979 Aug 8;64(2):171-9. doi: 10.1007/BF00496058.

DOI:10.1007/BF00496058
PMID:115037
Abstract

A rating scale for tardive dyskinesia was developed, consisting of nearly all signs seen by two groups of investigators over a 5-year period. Thirty-four items were included in the scale with a possibility of writing in idiosyncratic signs. The scale was shown to have good reliability and validity in studies carried out by both the New York and Boston groups. It is recommended as a suitable instrument for describing the breadth of tardive dyskinesia syndrome and also for quantifying the disorder. A second scale, "the abbreviated dyskinesia scale", contains 13 items which are more global than the items in the original scale. It also has been shown to be both reliable and valid. Its use is suited to situations requiring less extensively detailed assessments.

摘要

一种迟发性运动障碍评定量表被制定出来,它包含了两组研究人员在5年时间里所观察到的几乎所有症状。该量表包含34个项目,还可以记录特殊症状。纽约和波士顿的研究小组进行的研究表明,该量表具有良好的信度和效度。它被推荐为一种合适的工具,用于描述迟发性运动障碍综合征的范围以及对该疾病进行量化。第二个量表“简化运动障碍量表”包含13个项目,比原始量表中的项目更具综合性。它也已被证明具有信度和效度。它适用于需要不太详细评估的情况。

相似文献

1
A rating scale for tardive dyskinesia.迟发性运动障碍评定量表。
Psychopharmacology (Berl). 1979 Aug 8;64(2):171-9. doi: 10.1007/BF00496058.
2
Instrument measurement of lingual force variability reflects tardive tongue dyskinesia.舌力变异性的仪器测量反映迟发性舌运动障碍。
J Med Eng Technol. 2010 Jan;34(1):71-7. doi: 10.3109/03091900903402105.
3
A critical review of rating scales in the assessment of movement disorders in schizophrenia.
Curr Drug Targets. 2006 Sep;7(9):1225-9. doi: 10.2174/138945006778226589.
4
[Clinical characteristics of patients with tardive dyskinesias].
Fortschr Neurol Psychiatr. 2000 Jul;68(7):321-31. doi: 10.1055/s-2000-11805.
5
Intra-patient variability in the measurement of tardive dyskinesia.
Psychopharmacology (Berl). 1982;76(3):269-72. doi: 10.1007/BF00432559.
6
Sub-syndromes of tardive dyskinesia.迟发性运动障碍的亚综合征
Psychol Med. 1980 Aug;10(3):513-20. doi: 10.1017/s0033291700047401.
7
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.统一运动障碍评定量表:介绍与临床测量概况。
Mov Disord. 2008 Dec 15;23(16):2398-403. doi: 10.1002/mds.22341.
8
Reclassification of the tardive dyskinesia syndrome.
Adv Biochem Psychopharmacol. 1980;24:565-8.
9
Seven-year follow-up of tardive dyskinesia in Hungarian outpatients.
Neuropsychopharmacology. 1988 May;1(2):169-72. doi: 10.1016/0893-133x(88)90009-7.
10
Reliability and validity of a tardive dyskinesia videotape rating technique.迟发性运动障碍录像评分技术的可靠性和有效性。
Br J Psychiatry. 1982 May;140:508-15. doi: 10.1192/bjp.140.5.508.

引用本文的文献

1
A Systematic Review of Oral Vertical Dyskinesia ("Rabbit" Syndrome).口腔垂直运动障碍(“兔子”综合征)的系统评价。
Medicina (Kaunas). 2024 Aug 19;60(8):1347. doi: 10.3390/medicina60081347.
2
Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.亚洲的迟发性运动障碍——当前临床实践及神经科医生在护理流程中的作用
Front Neurol. 2024 Feb 14;15:1356761. doi: 10.3389/fneur.2024.1356761. eCollection 2024.
3
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.

本文引用的文献

1
[4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics].[4例抗精神病药治疗后出现的长期发展的面-颊-舌-咀嚼运动障碍]
Rev Neurol (Paris). 1959 Jun;100:751-5.
2
[Neurological complications of neuroleptic medication].[抗精神病药物的神经并发症]
Rev Neurol (Paris). 1959 Jun;100:553-95.
3
NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES.精神病药物治疗中的神经症状
抗精神病药剂量减少与继续用药治疗精神分裂症患者的比较。
Cochrane Database Syst Rev. 2022 Nov 24;11(11):CD014384. doi: 10.1002/14651858.CD014384.pub2.
4
Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.迟发性运动障碍:当前治疗方法聚焦
Focus (Am Psychiatr Publ). 2021 Jan;19(1):14-23. doi: 10.1176/appi.focus.20200038. Epub 2021 Jan 25.
5
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.临床实践中迟发性运动障碍影响的评估:共识小组建议
Neuropsychiatr Dis Treat. 2021 May 24;17:1589-1597. doi: 10.2147/NDT.S310605. eCollection 2021.
6
Tardive Dyskinesia: Treatment Update.迟发性运动障碍:治疗进展。
Curr Neurol Neurosci Rep. 2019 Aug 16;19(9):69. doi: 10.1007/s11910-019-0976-1.
7
[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].[抗精神病药物所致精神分裂症性精神病的运动症状 - 第3部分:迟发性运动障碍]
Nervenarzt. 2019 May;90(5):472-484. doi: 10.1007/s00115-018-0629-7.
8
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.ω-3 多不饱和脂肪酸辅助治疗首发精神病患者抑郁和焦虑症状的潜在作用:利培酮同期治疗的 16 周随机安慰剂对照试验的结果。
Schizophr Res. 2019 Feb;204:295-303. doi: 10.1016/j.schres.2018.09.006. Epub 2018 Sep 19.
9
Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration.热诱导脱水后抽动秽语综合征的缓解
Int J Phys Med Rehabil. 2018;6(3). doi: 10.4172/2329-9096.1000472. Epub 2018 Jun 13.
10
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.用于抗精神病药物所致迟发性运动障碍的γ-氨基丁酸激动剂
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD000203. doi: 10.1002/14651858.CD000203.pub4.
Acta Psychiatr Scand. 1964;40(1):10-27. doi: 10.1111/j.1600-0447.1964.tb05731.x.
4
[Significance of trigeminal degeneration in speech disorders in hereditary ataxia].
Nervenarzt. 1957 Jan 20;28(1):35-6.
5
A rating scale for extrapyramidal side effects.锥体外系副作用评定量表。
Acta Psychiatr Scand Suppl. 1970;212:11-9. doi: 10.1111/j.1600-0447.1970.tb02066.x.
6
Involuntary movements in a sample of chronic mental patients and their relation to the treatment with neuroleptics.
Int J Neuropsychiatry. 1967 Jun;3(3):286-91.
7
Eye color and tardive dyskinesia.
Psychopharmacol Bull. 1976 Apr;12(2):7, 8-9.
8
The assessment of tardive dyskinesia.
Arch Gen Psychiatry. 1977 Oct;34(10):1206-12. doi: 10.1001/archpsyc.1977.01770220088010.
9
An early clinical and toxicity trial of EX 11-582A in chronic schizophrenia.
Curr Ther Res Clin Exp. 1976 Jan;19(1):87-98.
10
Lithium in tardive dyskinesia.
Pharmakopsychiatr Neuropsychopharmakol. 1976 Mar;9(2):76-80. doi: 10.1055/s-0028-1094481.